J Korean Med Assoc.  2012 May;55(5):475-483. 10.5124/jkma.2012.55.5.475.

Recently developed therapeutic options for skin disorders

• Kang H

• KMID: 2064804
• DOI: http://doi.org/10.5124/jkma.2012.55.5.475

Abstract

The number of therapeutic options available to dermatologists for skin disorders has grown significantly over the past several years. Incorporating newly developed and recruited therapeutic modalities into the dermatologic field can promote a better overall treatment outcome and patient satisfaction while reducing common side effect. This article focuses to explore the current and new application of various therapeutic options for skin disorders. In particular, some mechanisms of action behind each therapy will be discussed. It is the hope that through this paper, clinicians will feel more comfortable choosing among these treatment options in their everyday practice of dermatology.

Keyword

Therapeutic option; Skin disorder; Dermatology

MeSH Terms

Dermatology
Patient Satisfaction
Skin
Treatment Outcome

Figure

• 

  Figure 1 Basic and specific pattern classification (From Lee WS, et al. J Am Acad Dermatol 2007;57:37-46) [28].

Reference

1. Bos JD, Van Leent EJ, Sillevis Smitt JH. The millennium criteria for the diagnosis of atopic dermatitis. Exp Dermatol. 1998. 7:132–138.

2. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008. 121:1337–1343.

3. Weidinger S, O'Sullivan M, Illig T, Baurecht H, Depner M, Rodriguez E, Ruether A, Klopp N, Vogelberg C, Weiland SK, McLean WH, von Mutius E, Irvine AD, Kabesch M. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol. 2008. 121:1203–1209.e1.

4. Lomax AR, Calder PC. Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans. Curr Pharm Des. 2009. 15:1428–1518.

5. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004. 113:1025–1034.

6. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001. 108:184–190.

7. Scanlon JV, Exter BP, Steinberg M, Jarvis CI. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. Ann Pharmacother. 2009. 43:1456–1465.

8. Schmitt J, Wozel G. Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics. 2009. 3:303–318.

9. Gospodarevskaya E, Picot J, Cooper K, Loveman E, Takeda A. Ustekinumab for the treatment of moderate to severe pso-riasis. Health Technol Assess. 2009. 13:Suppl 3. 61–66.

10. Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, Gottlieb AB. National Psoriasis Foundation. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009. 61:1044–1055.

11. Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2006. 44:1317–1323.

12. Zylicz Z, Krajnik M, Sorge AA, Costantini M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage. 2003. 26:1105–1112.

13. Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986. 115:227–232.

14. Taylor MN, Gonzalez ML. The practicalities of photodynamic therapy in acne vulgaris. Br J Dermatol. 2009. 160:1140–1148.

15. Massing AM, Epstein WL. Natural history of warts. A two-year study. Arch Dermatol. 1963. 87:306–310.

16. Morton CA, McKenna KE, Rhodes LE. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee and the British Photodermatology Group. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008. 159:1245–1266.

17. Robson KJ, Cunningham NM, Kruzan KL, Patel DS, Kreiter CD, O'Donnell MJ, Arpey CJ. Pulsed-dye laser versus conven-tional therapy in the treatment of warts: a prospective ran-domized trial. J Am Acad Dermatol. 2000. 43(2 Pt 1):275–280.

18. Micali G, Dall'Oglio F, Nasca MR, Tedeschi A. Management of cutaneous warts: an evidence-based approach. Am J Clin Dermatol. 2004. 5:311–317.

19. Hood R, Shermock KM, Emerman C. A prospective, randomized pilot evaluation of topical triple antibiotic versus mupirocin for the prevention of uncomplicated soft tissue wound infection. Am J Emerg Med. 2004. 22:1–3.

20. Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg. 2009. 28:15–18.

21. Shaheedi-Dadras M, Karami A, Mollaei F, Moravvej H, Malekzad F. The effect of methylprednisolone pulse-therapy plus oral cyclosporine in the treatment of alopecia totalis and universalis. Arch Iran Med. 2008. 11:90–93.

22. Ito T, Aoshima M, Ito N, Uchiyama I, Sakamoto K, Kawamura T, Yagi H, Hashizume H, Takigawa M. Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Arch Dermatol Res. 2009. 301:373–380.

23. Bikle DD, Elalieh H, Chang S, Xie Z, Sundberg JP. Development and progression of alopecia in the vitamin D receptor null mouse. J Cell Physiol. 2006. 207:340–353.

24. Sauerbrey A. Successful immunsuppression in childhood alopecia areata. Klin Padiatr. 2011. 223:244–245.

25. Inui S, Nakajima T, Toda N, Itami S. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: Retrospective analysis of 121 cases. J Dermatol. 2009. 36:323–327.

26. Ohyama M, Shimizu A, Tanaka K, Amagai M. Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata. J Dermatol Sci. 2010. 58:154–157.

27. Skurkovich S, Korotky NG, Sharova NM, Skurkovich B. Treatment of alopecia areata with anti-interferon-gamma antibodies. J Investig Dermatol Symp Proc. 2005. 10:283–284.

28. Lee WS, Ro BI, Hong SP, Bak H, Sim WY, Kim do W, Park JK, Ihm CW, Eun HC, Kwon OS, Choi GS, Kye YC, Yoon TY, Kim SJ, Kim HO, Kang H, Goo J, Ahn SY, Kim M, Jeon SY, Oh TH. A new classification of pattern hair loss that is universal for men and women: basic and specific (BASP) classification. J Am Acad Dermatol. 2007. 57:37–46.

29. Mounsey AL, Reed SW. Diagnosing and treating hair loss. Am Fam Physician. 2009. 80:356–362.

30. Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther. 2011. 5:489–495.

31. Alcala AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res. 2012. 18:33–39.

32. Suzuki D, Kobayashi R, Yasuda K, Yamamoto H, Morioka K, Mikawa M, Kobayashi K. Congenital dermatofibrosarcoma protuberans in a newborn infant with a massive back tumor: favorable effects of oral imatinib on the control of residual tumor growth. J Pediatr Hematol Oncol. 2011. 33:e304–e306.